ClinicalTrials.gg
CompletedNCT05745064Updated Nov 18, 2023

A Study of TL-925 as a Treatment for Dry Eye Disease

A Phase 2 interventional study of TL-925 and Placebo in Dry Eye Disease, sponsored by Telios Pharma, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Telios Pharma, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2023, 3 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.

Enrollment
174th of 473
107 · median 60
Started
2023
with 28 others
Phase 2
97 of 544
5 open now
Registered
428th of 544
by date

Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 174th largest by enrollment of the 473 interventional ones that give a count, is one of 29 that started in 2023, is one of 97 in phase 2, and was the 428th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 544 studies in Dry Eye Syndromes with a site in United States, or all of them as a file.
02

Study summary

In this prospective, Phase 2, multicenter, randomized, double-masked, placebo-controlled, parallel-arm study, approximately 100 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally BID.

The study will comprise two phases: 2-weeks screening/run-in and 4-weeks double-masked treatment.

03

Conditions studied

  • Dry Eye Disease

Browse trials for

Keywords

  • TL-925
  • Phase II
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals aged 18 years or older
  • A diagnosis of dry eye disease for at least 6 months
  • An unanesthetized Schirmer's test score (STS) of ≤ 10mm and ≥ 1mm in the study eye
  • A tear film break-up time (TFBUT) of ≤ 5 seconds in the study eye
  • A corneal fluorescein staining score of ≥ 2 in at least one region of the cornea
  • A sum corneal fluorescein staining score of ≥ 4 in the study eye
  • A total lissamine green conjunctival score of ≥ 2 in the study eye
  • Female subjects of and their male partners must both use a highly effective method during the study.

Exclusion criteria

Exclusion Criteria:

  • Any slit lamp finding
  • Any ongoing ocular infection (bacterial, viral or fungal) or active ocular inflammation
  • Any keratorefractive surgery within the last 12 months
  • Any intraocular or extraocular surgery within 3 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
107 participants (actual)

Study arms

  • Active comparator
    TL-925 Arm

    TL-925 will be administered OU BID

    Drug: TL-925

  • Placebo comparator
    Placebo Arm

    Placebo will be administered OU BID

    Drug: Placebo

Interventions

  • DrugTL-925

    TL-925 is an eye drop.

  • DrugPlacebo

    The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.

06

What researchers measure

Primary outcomes

  1. Adverse events during screening & treatment period

    Time frame: Baseline to the end of day 29 (±2 days)

Secondary outcomes

  1. Change from baseline in corneal and conjunctival staining

    Fluorescein staining by region in designated study eye will be used. Results will be assessed using a 5-point Corneal and Conjunctival Staining Scale.

    Time frame: Baseline to the end of day 29 (±2 days)

  2. Change from baseline in ocular discomfort

    Visual analog scale (VAS) will be used. This will assess patients on a a 7-item 100-point scale based on ocular discomfort.

    Time frame: Baseline to the end of day 29 (±2 days)

  3. Change from baseline visual acuity

    Best corrected visual acuity (BCVA) will be used to determine change in visual acuity from baseline.

    Time frame: Baseline to the end of day 29 (±2 days)

07

Study locations

4 sites
  • Aesthetic Eye Care
    Newport Beach, California 92663, United States
  • Vision Institute
    Colorado Springs, Colorado 80907, United States
  • Michael Washburn Center for Ophthalmic Research, LLC.
    Indianapolis, Indiana 46240, United States
  • Andover Eye Associates
    Andover, Massachusetts 01810, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Jul 2023, 4 months.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 4 months is below that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2023
First posted
Feb 27, 2023
StartActual
Feb 27, 2023
Primary completionActual
Jul 11, 2023
CompletionActual
Jul 11, 2023
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05745064
Lead sponsor
Telios Pharma, Inc.
Responsible party
Sponsor
First posted
Feb 27, 2023
Start date
Feb 27, 2023
Primary completion
Jul 11, 2023
Completion
Jul 11, 2023
Last update
Nov 18, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TL-925

Start the discussion